New Zealand Biotech
This article was originally published in Start Up
Executive Summary
The other land down under is getting serious about moving its affordable world-class science to global markets. For start-ups, establishing a US presence may be key. The three NZ start-ups that we profile in this issue--CoDa Therapeutics, Proacta and Protemix--have found their own paths for taking their technologies to the worldwide market via a US presence.
You may also be interested in...
CoDa Therapeutics Inc.
CoDa Therapeutics has novel wound care technology that suppresses connexins, the proteins that make up gap junctions. In preclinical studies the company's drugs reduced gap junction formation and communication, as well as inflammation, swelling and scarring, and doubled wound healing rates.
Proacta Inc.
Oncology drug developer Proacta Inc. is taking advantage of tumor hypoxia to activate a nontoxic prodrug to a cytotoxic chemotherapeutic. Since the agent acts only in areas of low oxygenation, it is nontoxic to normal tissues.
Protemix Corp. Ltd.
Protemix Corp. Ltd. is leveraging the expertise of its founder, internationally known scientist Garth Cooper, MD, PhD, to discover and develop novel therapies for preventing and treating diabetes and other metabolic disorders and their complications, as well as cardiovascular disease.